Biologics CDMO Tanvex launched Tanvex CDMO in 2023 to offer comprehensive biologic contract development and manufacturing services, signaling a potential opportunity to position CDMO capabilities for partnerships in biosimilars and novel biologics.

Biosimilar Growth With a biosimilar portfolio including the recent US launch of Nypozi (filgrastim) via a marketing partner, there is a pathway to explore distribution, co-development, or contracted manufacturing opportunities in US biosimilar supply chains.

Strategic Partnerships Recent collaboration with Alcami and the formation of CDMO operations indicate openness to partner-driven development and manufacturing programs, suggesting outreach for joint development, analytical services, and scale-up collaborations.

Legal & IP Landscape Past patent litigation related to TX-05 highlights IP risk considerations; engaging early with Tanvex on safe harbor, freedom-to-operate assessments, and collaborative risk-sharing models could facilitate smoother market entry and co-development deals.

Financial & Scale Revenue range of $50M-$100M and a mid-size employee base imply a growing but still nimble organization; sales outreach can target mid-to-large biologics programs seeking reliable manufacturing, process development, and scale-up capabilities to support expansion plans.